An algorithm for identifying chronic kidney disease in the French national health insurance claims database.


Journal

Nephrologie & therapeutique
ISSN: 1872-9177
Titre abrégé: Nephrol Ther
Pays: France
ID NLM: 101248950

Informations de publication

Date de publication:
Jul 2022
Historique:
received: 04 03 2022
accepted: 11 03 2022
pubmed: 1 7 2022
medline: 27 7 2022
entrez: 30 6 2022
Statut: ppublish

Résumé

Published algorithms for identifying chronic kidney disease in healthcare claims databases have poor performance except in patients with renal replacement therapy. We propose and describe an algorithm to identify all stage chronic kidney disease in a French healthcare claims databases and assessed its performance by using data from the Renal Epidemiology and Information Network registry and the French Childhood Cancer Survivor Study cohort. A group of experts met several times to define a list of items and combinations of items that could be related to chronic kidney disease. For the French Childhood Cancer Survivor Study cohort, information on confirmed chronic kidney disease cases extracted from medical records was considered the gold standard (KDIGO definition). Sensitivity, specificity, and positive and negative predictive value and kappa coefficients were estimated. The contribution of each component of the algorithm was assessed for 1 and 2 years before the start of renal replacement therapy for confirmed end-stage kidney disease in the Renal Epidemiology and Information Network registry. The algorithm's sensitivity was 78%, specificity 97.4%, negative predictive value 98.4% and positive predictive value 68.7% in French Childhood Cancer Survivor Study cohort and the kappa coefficient was 0.79 for agreement with the gold standard. The algorithm 93.6% and 55.1% of confirmed incident end-stage kidney disease cases from the Renal Epidemiology and Information Network registry when considering 1 year and 2 years, respectively, before renal replacement therapy start. The algorithm showed good performance among younger patients and those with end-stage kidney disease in the twol last years prior to renal replacement therapy. Future research will address the ability of the algorithm to detect early chronic kidney disease stages and to classify the severity of chronic kidney disease.

Sections du résumé

BACKGROUND BACKGROUND
Published algorithms for identifying chronic kidney disease in healthcare claims databases have poor performance except in patients with renal replacement therapy. We propose and describe an algorithm to identify all stage chronic kidney disease in a French healthcare claims databases and assessed its performance by using data from the Renal Epidemiology and Information Network registry and the French Childhood Cancer Survivor Study cohort.
METHODS METHODS
A group of experts met several times to define a list of items and combinations of items that could be related to chronic kidney disease. For the French Childhood Cancer Survivor Study cohort, information on confirmed chronic kidney disease cases extracted from medical records was considered the gold standard (KDIGO definition). Sensitivity, specificity, and positive and negative predictive value and kappa coefficients were estimated. The contribution of each component of the algorithm was assessed for 1 and 2 years before the start of renal replacement therapy for confirmed end-stage kidney disease in the Renal Epidemiology and Information Network registry.
RESULTS RESULTS
The algorithm's sensitivity was 78%, specificity 97.4%, negative predictive value 98.4% and positive predictive value 68.7% in French Childhood Cancer Survivor Study cohort and the kappa coefficient was 0.79 for agreement with the gold standard. The algorithm 93.6% and 55.1% of confirmed incident end-stage kidney disease cases from the Renal Epidemiology and Information Network registry when considering 1 year and 2 years, respectively, before renal replacement therapy start.
CONCLUSIONS CONCLUSIONS
The algorithm showed good performance among younger patients and those with end-stage kidney disease in the twol last years prior to renal replacement therapy. Future research will address the ability of the algorithm to detect early chronic kidney disease stages and to classify the severity of chronic kidney disease.

Identifiants

pubmed: 35773142
pii: S1769-7255(22)00086-4
doi: 10.1016/j.nephro.2022.03.003
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

255-262

Informations de copyright

Copyright © 2022. Published by Elsevier Masson SAS.

Auteurs

Imène Mansouri (I)

EPI-PHARE (French National Agency for Medicines and Health Products Safety [ANSM] and French National Health Insurance [CNAM]), Saint-Denis, France; Center for research epidemiology and population health, Radiation epidemiology team, Université Paris-Saclay, Université Paris-Sud, UVSQ, 94805 Villejuif, France.

Maxime Raffray (M)

University Rennes, EHESP, REPERES (Recherche en pharmaco-épidémiologie et recours aux soins)-EA 7449, 35000 Rennes, France.

Mathilde Lassalle (M)

REIN registry, Agence de la biomédecine, 1, avenue du Stade de France, 93212 Saint-Denis-La Plaine, France.

Florent de Vathaire (F)

Center for research epidemiology and population health, Radiation epidemiology team, Université Paris-Saclay, Université Paris-Sud, UVSQ, 94805 Villejuif, France; Department of children and adolescent oncology, Gustave-Roussy, Université Paris-Saclay, 94805 Villejuif, France.

Brice Fresneau (B)

Department of children and adolescent oncology, Gustave-Roussy, Université Paris-Saclay, 94805 Villejuif, France; Cancer and Radiation, CESP, Unit 1018 Inserm, Villejuif, France.

Chiraz Fayech (C)

Department of children and adolescent oncology, Gustave-Roussy, Université Paris-Saclay, 94805 Villejuif, France; Cancer and Radiation, CESP, Unit 1018 Inserm, Villejuif, France.

Hélène Lazareth (H)

Service Évaluation et Outils pour la Qualité et la Sécurité des Soins, Direction de l'Amélioration de la Qualité et de la Sécurité des Soins, Haute Autorité de santé, Saint-Denis, France.

Nadia Haddy (N)

Center for research epidemiology and population health, Radiation epidemiology team, Université Paris-Saclay, Université Paris-Sud, UVSQ, 94805 Villejuif, France; Department of children and adolescent oncology, Gustave-Roussy, Université Paris-Saclay, 94805 Villejuif, France.

Sahar Bayat (S)

University Rennes, EHESP, REPERES (Recherche en pharmaco-épidémiologie et recours aux soins)-EA 7449, 35000 Rennes, France.

Cécile Couchoud (C)

University Rennes, EHESP, REPERES (Recherche en pharmaco-épidémiologie et recours aux soins)-EA 7449, 35000 Rennes, France; Université Lyon I, CNRS, UMR 5558, Laboratoire de biométrie et biologie évolutive, équipe biostatistique santé, Villeurbanne, France. Electronic address: cecile.couchoud@biomedecine.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH